A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 212 participants.
Also called NCT05659537
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 212 participants
- Sponsor
- Registry
-
NCT05659537
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- India
- Registry status
- Completed
Technical summary
Registry record NCT05659537. Allocation not applicable; no masking; primary purpose treatment. Start 2022-12-29 (actual); primary completion 2024-01-16 (actual). Results posted on 2025-02-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Dulaglutide
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05659537- Content hash
0dbfb13abe8d6d7110e1459c0a57dd18f2c14cb9426171f4ff4471908eb969d0